Fate Therapeutics, Inc. (FATE)
Upgrades & Downgrades
Latest FATE news
Fate Therapeutics to Participate at Upcoming September Investor Conferences
2 September 2022
SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of ...
The 5 Top Stocks Cathie Wood Is Buying Now
15 August 2022
Cathie Wood's Ark Invest has performed well recently, with shares of her flagship exchange-traded fund (ETF), the ARK Innovation ETF (NYSEMKT: ARKK ), up more than 15% during the past month. The perfo...
3 Cathie Wood Stocks for the Future
14 August 2022
Unlike a lot of tech investors, Cathie Wood is super bullish on biotechnology. Here are three of her picks that these Motley Fool contributors love.
Cathie Wood Is Buying Up Red-Hot Fate Therapeutics (FATE) Stock
12 August 2022
Source: ra2 studio/Shutterstock Shares of Fate Therapeutics (NASDAQ: FATE ) stock are up 3% following a massive purchase by two of Cathie Wood's exchange-traded funds (ETFs). Fate is a clinical stage ...
ARK's Cathie Wood Dumps More Twitter Stock, Buys $20M in Fate Therapeutics Stock
12 August 2022
Cathie Wood-led Ark Investment Management has bought 628,060 shares of clinical-stage biopharmaceutical company Fate Therapeutics Inc. (NASDAQ: FATE) through two of the firm's exchange-traded funds (E...
7 Small-Cap Stocks to Buy Before the Bull Market Returns
7 August 2022
Small-cap stocks with lower market capitalizations ranging from $300 million to $2 billion have taken quite a hit since January. These stocks typically belong to smaller companies with massive long-te...
FATE's Q2 Loss Narrower Than Expected, Pipeline in Focus
4 August 2022
FATE reports a narrower loss and higher collaboration revenues in the second quarter.
Fate Therapeutics Inc. (FATE) CEO Scott Wolchko on Q2 2022 Results - Earnings Call Transcript
4 August 2022
Fate Therapeutics Inc. (NASDAQ:FATE ) Q2 2022 Earnings Conference Call August 3, 2022 5:00 PM ET Company Participants Scott Wolchko - President and CEO Ed Dulac - CFO Yu-Waye Chu - Chief Medical Offic...
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
3 August 2022
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 8.14% and 38.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2022 Financial Results
25 July 2022
SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of p...